Duke University Medical Center Seeley G. Mudd Bldg.

Durham, North Carolina 27710

0 studies enrolling now · 4 studies all time

What they study most

Hematologic Malignancies, PI3K Pathway Activated Tumors, Solid Tumor, Solid Tumor and Hematologic Malignancies, Tumors With Aberrations in ALK or ROS1

Studies at this site

• Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) — Stopped early
• MEK162 for Patients With RAS/RAF/MEK Activated Tumors — Completed
• BGJ398 for Patients With Tumors With FGFR Genetic Alterations — Stopped early
• BKM120 for Patients With PI3K-activated Tumors — Completed